Skip to main content

Blood therapy giant CSL reports better than expected NPAT | CSL (ASX:CSL) Reporting Results

Jessica Amir
August 18, 2021

The biggest blood therapy company in the world and the second biggest vaccine company, CSL (ASX:CSL) reported its FY21 results.

CSL reported its NPAT jumped 13% to US$2.375 billion. This is 2% above market expectations. Profit growth was boosted by CSL’s Seqirus division, its flu vaccine business, which saw a 30% revenue boost. However, CSL’s Behring division, its blood therapy business, was severely impacted by COVID-19 restrictions.

CSL’s group revenue rose 13% to US$10.3 billion, while CSL’s cashflow from operations surged 46% to US$3.6 billion.

CSL declared a final dividend of US$1.18ps (AU$1.61ps), payable on 30th September. CSL’s total full year dividends increased 10% to US$2.22 per share.

CSL’s FY22 outlook views profit to fall between US$2.15 billion to US$2.25 billion.

CSL is a Morgan Stanley, Macquarie, Citi and Credit Suisse HOLD stock. UBS and Morgans have CSL as a BUY stock.

CSL shares surged to $302.80, at its highest level since June. However, traders quickly took profits, and CSL is now trading at $294.83.

Morning Bell 22 January

Grady Wulff
January 22, 2024

Weekly Wrap 19 January

Sophia Mavridis
January 19, 2024

Morning Bell 19 January

Sam Kanaan
January 19, 2024

Morning Bell 18 January

Grady Wulff
January 18, 2024

Morning Bell 17 January

Grady Wulff
January 17, 2024

Morning Bell 16 January

Grady Wulff
January 16, 2024

Morning Bell 15 January

Sophia Mavridis
January 15, 2024

Weekly Wrap 15 December

Grady Wulff
December 15, 2023

Morning Bell 14 December

Grady Wulff
December 14, 2023

Morning Bell 13 December

Grady Wulff
December 13, 2023